Physician profile
Michael J Duran
NPI 1700888229
$2,998.76
in general payments reported to CMS, 2019-2025
26 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $757 · 2021: $164 · 2022: $696 · 2023: $456 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,127.82 | 2020-2023 | Ensite, Ensite Precision, Xience Sierra |
| Novartis Pharmaceuticals Corporation | $224.82 | 2019-2023 | |
| Astellas Pharma US INC | $222.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $170.20 | 2019-2023 | |
| Smith+Nephew, INC. | $149.99 | 2025 | Redapt |
| Boston Scientific Corporation | $147.52 | 2023-2025 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $119.32 | 2019-2023 | Xarelto |
| Abiomed | $117.80 | 2022 | |
| Pfizer INC. | $115.18 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $98.89 | 2022-2023 | Verquvo |
| Amarin Pharma, INC. | $88.15 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.01 | 2022-2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $56.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.54 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $38.62 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $35.36 | 2019 | |
| Daiichi Sankyo INC. | $28.55 | 2022 | |
| Medtronic, INC. | $19.83 | 2022 | |
| Gilead Sciences, INC. | $16.99 | 2019 | |
| Angiodynamics, INC. | $15.43 | 2021 | |
| Edwards Lifesciences Corporation | $14.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.27 | 2022 | |
| Amgen INC. | $12.09 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.48 | 2021 | |
| Lundbeck LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Duran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.